News Website

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

20 chocolate Easter eggs later: A nutritionist’s sweet survival guide to see you through the holiday weekend - The Irish News

20 chocolate Easter eggs later: A nutritionist’s sweet survival guide to see you through the holiday weekend The Irish News

Published: April 17, 2025, 5 a.m.

Read Full Article

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma MedPage Today

Published: April 9, 2025, 3:15 p.m.

Read Full Article

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer 2 Minute Medicine

Published: March 17, 2025, 11:07 p.m.

Read Full Article

Robotic-assisted laparoscopy increases endometrial cancer survival rates - Contemporary Obgyn

Robotic-assisted laparoscopy increases endometrial cancer survival rates Contemporary Obgyn

Published: March 13, 2025, 5:15 p.m.

Read Full Article

Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients - Nature.com

Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients Nature.com

Published: March 6, 2025, 6:11 a.m.

Read Full Article

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com

Published: March 5, 2025, 11:04 a.m.

Read Full Article

Latest Articles

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

20 chocolate Easter eggs later: A nutritionist’s sweet survival guide to see you through the holiday weekend - The Irish News

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine

Robotic-assisted laparoscopy increases endometrial cancer survival rates - Contemporary Obgyn

Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Subscribe to Our Newsletter